Xuhui Bao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Xuhui Bao has a total of 56 co-authors. Here are the top co-authors by number of shared publications:
- Chuan-Yuan Li
Chinese Institute for Molecular and Cellular Therapeutics, Chinese Institutes for Medical Research, Beijing, China
10 shared publications - Meng Jiao
Department of Dermatology, Duke University Medical Center, Durham, North Carolina
10 shared publications - Dong Pan
Department of Shandong Provincial Key Laboratory of Precision Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China
9 shared publications - Fang Li
Department of Dermatology, Duke University Medical Center, Durham, North Carolina
9 shared publications - Mengjie Hu
Department of Dermatology, Duke University Medical Center, Durham, North Carolina
9 shared publications - Chen Yu
Department of Ophthalmology, Duke University School of Medicine, Durham, USA
8 shared publications
Latest Publications
- Open Access
- 8 October 2026
- Published by Elsevier in SSRN Electronic Journal
Real-world Evidence Supporting Full Regulatory Approval of Mindeudesivir for COVID-19: Effectiveness and Safety from a Post-conditional Approval Cohort
Background: Existing evidence for mindeudesivir comes exclusively from randomized controlled trials with strict eligibility criteria. We conducted a real-world study to evaluate its efficacy and safety in patients with mild-to-moderate COVID-19.Methods:In this retrospective cohort study (NCT06142201), data were extracted from Shanghai Pudong Hospital’s electronic medical records (January-August 2023). Outcomes of mindeudesivir recipients were compared with controls (no anti-SARS-CoV-2 therapy) using 1:1 propensity score matching and inverse probability of treatment weighting. The primary endpoint was 28-day disease progression (severe COVID-19 or all-cause mortality). Findings: Of 7250 eligible patients, 2550 per group were matched. Mindeudesivir reduced disease progression by 9.3% (2.6% vs. 11.9%; 95% CI: -10.7% to -7.8%; p < 0.0001), with a risk ratio (RR) of 0.22, an adjusted odds ratio (OR) of 0.16 (95% CI: 0.12–0.22), and a number needed to treat (NNT) of 10.8. Among hospitalized patients (n = 148 per group), the absolute risk reduction was 11.5% (7.4% vs. 18.9%; 95% CI: -19.8% to -3.2%; Barnard’s exact test p = 0.0018, Fisher’s exact test p = 0.0027), with an RR of 0.39, an adjusted OR of 0.35 (95% CI: 0.17–0.74), and an NNT of 8.7. Sensitivity and subgroup analyses were consistent with the primary analysis.Interpretation: Mindeudesivir significantly reduced disease progression risk in patients with mild-to-moderate COVID-19 in real-world clinical practice.Funding:This study was sponsored by Shanghai Junshi Biosciences Co., LTD., and partially funded by 2026 Pudong New Area Regulatory Science Research Project (Contract No. 20260609-663 to X.B.) and the Healthcare Talents Elite Program of Shanghai Pudong New Area (Grant No. 2025PDWSYCBJ-06, to X.B.).
- 8 October 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessReal-world Evidence Supporting Full Regulatory Approval of Mindeudesivir for COVID-19: Effectiveness and Safety from a Post-conditional Approval Cohort
Background: Existing evidence for mindeudesivir comes exclusively from randomized controlled trials with strict eligibility criteria. We conducted a real-world study to evaluate its efficacy and safety in patients with mild-to-moderate COVID-19.Methods:In this retrospective cohort study (NCT06142201), data were extracted from Shanghai Pudong Hospital’s electronic medical records (January-August 2023). Outcomes of mindeudesivir recipients were compared with controls (no anti-SARS-CoV-2 therapy) using 1:1 propensity score matching and inverse probability of treatment weighting. The primary endpoint was 28-day disease progression (severe COVID-19 or all-cause mortality). Findings: Of 7250 eligible patients, 2550 per group were matched. Mindeudesivir reduced disease progression by 9.3% (2.6% vs. 11.9%; 95% CI: -10.7% to -7.8%; p < 0.0001), with a risk ratio (RR) of 0.22, an adjusted odds ratio (OR) of 0.16 (95% CI: 0.12–0.22), and a number needed to treat (NNT) of 10.8. Among hospitalized patients (n = 148 per group), the absolute risk reduction was 11.5% (7.4% vs. 18.9%; 95% CI: -19.8% to -3.2%; Barnard’s exact test p = 0.0018, Fisher’s exact test p = 0.0027), with an RR of 0.39, an adjusted OR of 0.35 (95% CI: 0.17–0.74), and an NNT of 8.7. Sensitivity and subgroup analyses were consistent with the primary analysis.Interpretation: Mindeudesivir significantly reduced disease progression risk in patients with mild-to-moderate COVID-19 in real-world clinical practice.Funding:This study was sponsored by Shanghai Junshi Biosciences Co., LTD., and partially funded by 2026 Pudong New Area Regulatory Science Research Project (Contract No. 20260609-663 to X.B.) and the Healthcare Talents Elite Program of Shanghai Pudong New Area (Grant No. 2025PDWSYCBJ-06, to X.B.).
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Video S1 from Targeting Catechol-O-Methyltransferase Induces Mitochondrial Dysfunction and Enhances the Efficacy of Radiotherapy in Glioma
Supplementary Video S1 from Targeting Catechol-O-Methyltransferase Induces Mitochondrial Dysfunction and Enhances the Efficacy of Radiotherapy in Glioma
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Video S1 from Targeting Catechol-O-Methyltransferase Induces Mitochondrial Dysfunction and Enhances the Efficacy of Radiotherapy in Glioma
Supplementary Video S1 from Targeting Catechol-O-Methyltransferase Induces Mitochondrial Dysfunction and Enhances the Efficacy of Radiotherapy in Glioma
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Data from Targeting Catechol-O-Methyltransferase Induces Mitochondrial Dysfunction and Enhances the Efficacy of Radiotherapy in Glioma
Supplementary figures and tables
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from Targeting Catechol-O-Methyltransferase Induces Mitochondrial Dysfunction and Enhances the Efficacy of Radiotherapy in Glioma
Supplementary figures and tables
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Data from Targeting Catechol-O-Methyltransferase Induces Mitochondrial Dysfunction and Enhances the Efficacy of Radiotherapy in Glioma
Radiotherapy (RT) is commonly used to try to eliminate any remaining tumor cells following surgical resection of glioma. However, tumor recurrence is prevalent, highlighting the unmet medical need to develop therapeutic strategies to enhance the efficacy of RT in glioma. Focusing on the radiosensitizing potential of the currently approved drugs known to cross the blood-brain barrier can facilitate rapid clinical translation. Here, we assessed the role of catechol-O-methyltransferase (COMT), a key enzyme to degrade catecholamines and a drug target for Parkinson’s disease, in glioma treatment. Analysis of The Cancer Genome Atlas data showed significantly higher COMT expression levels in both low-grade glioma and glioblastoma compared to normal brain tissues. Inhibition of COMT by genetic knockout or FDA-approved COMT inhibitors significantly sensitized glioma cells to RT in vitro and in vivo. Mechanistically, COMT inhibition in glioma cells led to mitochondria dysfunction and increased mitochondrial RNA release into the cytoplasm, activating the cellular antiviral double-stranded RNA sensing pathway and type I interferon (IFN) response. Elevated type I IFNs stimulated the phagocytic capacity of microglial cells, enhancing RT efficacy. Given the long-established safety record of the COMT inhibitors, these findings provide a solid rationale to evaluate them in combination with RT in patients with glioma.Significance:Inhibition of catechol-O-methyltransferase, a well-established drug target in Parkinson’s disease, interferes with mitochondrial electron transport and induces mitochondrial double-stranded RNA leakage, activating type I interferon signaling and sensitizing glioma to radiotherapy.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Targeting Catechol-O-Methyltransferase Induces Mitochondrial Dysfunction and Enhances the Efficacy of Radiotherapy in Glioma
Radiotherapy (RT) is commonly used to try to eliminate any remaining tumor cells following surgical resection of glioma. However, tumor recurrence is prevalent, highlighting the unmet medical need to develop therapeutic strategies to enhance the efficacy of RT in glioma. Focusing on the radiosensitizing potential of the currently approved drugs known to cross the blood-brain barrier can facilitate rapid clinical translation. Here, we assessed the role of catechol-O-methyltransferase (COMT), a key enzyme to degrade catecholamines and a drug target for Parkinson’s disease, in glioma treatment. Analysis of The Cancer Genome Atlas data showed significantly higher COMT expression levels in both low-grade glioma and glioblastoma compared to normal brain tissues. Inhibition of COMT by genetic knockout or FDA-approved COMT inhibitors significantly sensitized glioma cells to RT in vitro and in vivo. Mechanistically, COMT inhibition in glioma cells led to mitochondria dysfunction and increased mitochondrial RNA release into the cytoplasm, activating the cellular antiviral double-stranded RNA sensing pathway and type I interferon (IFN) response. Elevated type I IFNs stimulated the phagocytic capacity of microglial cells, enhancing RT efficacy. Given the long-established safety record of the COMT inhibitors, these findings provide a solid rationale to evaluate them in combination with RT in patients with glioma.Significance:Inhibition of catechol-O-methyltransferase, a well-established drug target in Parkinson’s disease, interferes with mitochondrial electron transport and induces mitochondrial double-stranded RNA leakage, activating type I interferon signaling and sensitizing glioma to radiotherapy.
- 8 August 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Immunology
- Vol. 10 (110) , eadq2055
A noncanonical cytoplasmic role for BUB1 in restraining DNA damage–induced dsRNA accumulation and sensing within stress granules
Budding uninhibited by benzimidazoles 1 (BUB1) is a nuclear serine/threonine protein kinase that ensures proper chromosome segregation before mitosis. We report that BUB1 plays an unexpected cytoplasmic role in restraining DNA damage–induced accumulation of cytoplasmic dsRNA and the ensuing immune response. Tumors deficient in BUB1 were sensitive to radiotherapy in a CD8 T cell–dependent manner. We found increased immune cell infiltration accompanied by elevated type I interferon production from irradiated BUB1-deficient cells caused by enhanced cytoplasmic dsRNA accumulation and activation of the MDA5/MAVS dsRNA-sensing pathway. Mechanistically, we found that after radiation exposure, BUB1 underwent nucleus-to-cytoplasm migration, where it bound and phosphorylated the poly(A)-binding protein PABPC1, which was degraded together with its associated messenger RNAs stored in the stress granules, thereby preventing dsRNA accumulation and activation of the innate immune response.
- 8 August 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Immunology
- Vol. 10 (110) , eadq2055
A noncanonical cytoplasmic role for BUB1 in restraining DNA damage–induced dsRNA accumulation and sensing within stress granules
Budding uninhibited by benzimidazoles 1 (BUB1) is a nuclear serine/threonine protein kinase that ensures proper chromosome segregation before mitosis. We report that BUB1 plays an unexpected cytoplasmic role in restraining DNA damage–induced accumulation of cytoplasmic dsRNA and the ensuing immune response. Tumors deficient in BUB1 were sensitive to radiotherapy in a CD8 T cell–dependent manner. We found increased immune cell infiltration accompanied by elevated type I interferon production from irradiated BUB1-deficient cells caused by enhanced cytoplasmic dsRNA accumulation and activation of the MDA5/MAVS dsRNA-sensing pathway. Mechanistically, we found that after radiation exposure, BUB1 underwent nucleus-to-cytoplasm migration, where it bound and phosphorylated the poly(A)-binding protein PABPC1, which was degraded together with its associated messenger RNAs stored in the stress granules, thereby preventing dsRNA accumulation and activation of the innate immune response.
- Open Access
- 4 November 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Video S2 from Targeting Catechol-O-Methyltransferase Induces Mitochondrial Dysfunction and Enhances the Efficacy of Radiotherapy in Glioma
Supplementary Video S2 from Targeting Catechol-O-Methyltransferase Induces Mitochondrial Dysfunction and Enhances the Efficacy of Radiotherapy in Glioma
- 4 November 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Video S2 from Targeting Catechol-O-Methyltransferase Induces Mitochondrial Dysfunction and Enhances the Efficacy of Radiotherapy in Glioma
Supplementary Video S2 from Targeting Catechol-O-Methyltransferase Induces Mitochondrial Dysfunction and Enhances the Efficacy of Radiotherapy in Glioma
- Open Access
- 4 November 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Data from Targeting Catechol-O-Methyltransferase Induces Mitochondrial Dysfunction and Enhances the Efficacy of Radiotherapy in Glioma
Supplementary figures and tables
- 4 November 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from Targeting Catechol-O-Methyltransferase Induces Mitochondrial Dysfunction and Enhances the Efficacy of Radiotherapy in Glioma
Supplementary figures and tables
- Open Access
- 4 November 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Video S1 from Targeting Catechol-O-Methyltransferase Induces Mitochondrial Dysfunction and Enhances the Efficacy of Radiotherapy in Glioma
Supplementary Video S1 from Targeting Catechol-O-Methyltransferase Induces Mitochondrial Dysfunction and Enhances the Efficacy of Radiotherapy in Glioma
- 4 November 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Video S1 from Targeting Catechol-O-Methyltransferase Induces Mitochondrial Dysfunction and Enhances the Efficacy of Radiotherapy in Glioma
Supplementary Video S1 from Targeting Catechol-O-Methyltransferase Induces Mitochondrial Dysfunction and Enhances the Efficacy of Radiotherapy in Glioma
- Open Access
- 1 August 2024
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 84 (21) , 3640-3656
Targeting Catechol-O-Methyltransferase Induces Mitochondrial Dysfunction and Enhances the Efficacy of Radiotherapy in Glioma
Radiotherapy (RT) is commonly used to try to eliminate any remaining tumor cells following surgical resection of glioma. However, tumor recurrence is prevalent, highlighting the unmet medical need to develop therapeutic strategies to enhance the efficacy of RT in glioma. Focusing on the radiosensitizing potential of the currently approved drugs known to cross the blood-brain barrier can facilitate rapid clinical translation. Here, we assessed the role of catechol-O-methyltransferase (COMT), a key enzyme to degrade catecholamines and a drug target for Parkinson’s disease, in glioma treatment. Analysis of The Cancer Genome Atlas data showed significantly higher COMT expression levels in both low-grade glioma and glioblastoma compared to normal brain tissues. Inhibition of COMT by genetic knockout or FDA-approved COMT inhibitors significantly sensitized glioma cells to RT in vitro and in vivo. Mechanistically, COMT inhibition in glioma cells led to mitochondria dysfunction and increased mitochondrial RNA release into the cytoplasm, activating the cellular antiviral double-stranded RNA sensing pathway and type I interferon (IFN) response. Elevated type I IFNs stimulated the phagocytic capacity of microglial cells, enhancing RT efficacy. Given the long-established safety record of the COMT inhibitors, these findings provide a solid rationale to evaluate them in combination with RT in patients with glioma. Significance: Inhibition of catechol-O-methyltransferase, a well-established drug target in Parkinson’s disease, interferes with mitochondrial electron transport and induces mitochondrial double-stranded RNA leakage, activating type I interferon signaling and sensitizing glioma to radiotherapy.
- 1 August 2024
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 84 (21) , 3640-3656
Open AccessTargeting Catechol-O-Methyltransferase Induces Mitochondrial Dysfunction and Enhances the Efficacy of Radiotherapy in Glioma
Radiotherapy (RT) is commonly used to try to eliminate any remaining tumor cells following surgical resection of glioma. However, tumor recurrence is prevalent, highlighting the unmet medical need to develop therapeutic strategies to enhance the efficacy of RT in glioma. Focusing on the radiosensitizing potential of the currently approved drugs known to cross the blood-brain barrier can facilitate rapid clinical translation. Here, we assessed the role of catechol-O-methyltransferase (COMT), a key enzyme to degrade catecholamines and a drug target for Parkinson’s disease, in glioma treatment. Analysis of The Cancer Genome Atlas data showed significantly higher COMT expression levels in both low-grade glioma and glioblastoma compared to normal brain tissues. Inhibition of COMT by genetic knockout or FDA-approved COMT inhibitors significantly sensitized glioma cells to RT in vitro and in vivo. Mechanistically, COMT inhibition in glioma cells led to mitochondria dysfunction and increased mitochondrial RNA release into the cytoplasm, activating the cellular antiviral double-stranded RNA sensing pathway and type I interferon (IFN) response. Elevated type I IFNs stimulated the phagocytic capacity of microglial cells, enhancing RT efficacy. Given the long-established safety record of the COMT inhibitors, these findings provide a solid rationale to evaluate them in combination with RT in patients with glioma. Significance: Inhibition of catechol-O-methyltransferase, a well-established drug target in Parkinson’s disease, interferes with mitochondrial electron transport and induces mitochondrial double-stranded RNA leakage, activating type I interferon signaling and sensitizing glioma to radiotherapy.